Table 1. Clinical and molecular characteristics of the 98 probands.
| Amsterdam I (N = 31) | Amsterdam II (N = 22) | Bethesda (N = 45) | Total n° (N = 98) |
||||
|---|---|---|---|---|---|---|---|
| Gender | |||||||
| M | 14 | 12 | 20 | 46 | |||
| F | 17 | 10 | 25 | 52 | |||
| Diagnosis age | |||||||
| <50 | 19 | 6 | 31 | 56 | |||
| >50 | 12 | 16 | 14 | 42 | |||
| Tumor type | |||||||
| CRC | 31 | 18 | 42 | 91 | |||
| Breast | 0 | 0 | 1 | 1 | |||
| Gastric | 0 | 1 | 1 | 2 | |||
| Other tumors | 0 | 3 | 1 | 4 | |||
| MSI result | |||||||
| MSI | 6 | 1 | 4 | 11 | |||
| MSS | 19 | 17 | 27 | 63 | |||
| Unknown | 6 | 4 | 14 | 24 | |||
| IHC result | |||||||
| MMR-presence | 21 | 16 | 18 | 55 | |||
| MMR-absence | 4 | 1 | 4 | 9 | |||
| Unknown | 6 | 5 | 23 | 34 | |||
| MMR gene test | |||||||
| MMR wt | 28 | 21 | 33 | 82 | |||
| Unknown | 3 | 1 | 12 | 16 | |||
N: number of patients; M: male; F: female; CRC: colorectal cancer; MSI: microsatellite instability; MSS: microsatellite stable; IHC: immunohistochemistry; MMR: mismatch repair; wt: wild type.